Quite apart from the fact that this is a revenue opportunity for...

Quite apart from the fact that this is a revenue opportunity for Benitec, David Suhy (the designer of TT-034) is also a scientific adviser to Regen. I am very impressed with David. His presentation to the RAC was outstanding. Of course, it is clear (from previous posts claiming that all patients in the TT-034 trial were already dosed when in fact no patients had been dosed at the time) that some Benitec critics did not even watch that RAC video because, if they had, they would have known that the TT-034 trial was a dose escalating trial and all 14 patients were NEVER going to be dosed at the same time. These same critics may well scoff at HotCopper readers being interested in Regen but we are educated and sophisticated readers here on HC who take great interest in the activities of our key scientific personnel and don't take to B*ll S!&T, so why wouldn't we be interested in Regen and a treatment for breast cancer?